Apyx Medical Raises $10M to Fuel Growth in Surgical Aesthetics

NEW YORK, NY – November 18, 2025 – Apyx Medical Corporation (Nasdaq: APYX) announced today the pricing of a $10 million public offering of approximately 2.76 million shares of its common stock. The offering, priced at $3.62 per share, is intended to strengthen the company’s financial position and support its strategic initiatives in the rapidly evolving surgical aesthetics market.

Funding Innovation and Market Expansion

The capital infusion comes at a pivotal time for Apyx Medical, a company specializing in Helium Plasma Technology, marketed under brands like Renuvion and the AYON Body Contouring System. Proceeds from the offering will be allocated towards working capital, general corporate purposes, and continued investment in research and development. According to a company statement, this financial flexibility will enable Apyx Medical to capitalize on emerging opportunities within the aesthetic industry and accelerate the commercialization of its innovative technologies. “This offering allows us to proactively address our capital needs and pursue growth initiatives that align with our long-term strategy,” stated a company representative.

The surgical aesthetics market is experiencing robust growth, driven by increasing consumer demand for non-invasive and minimally invasive procedures. Market analysts predict the global aesthetic medicine market will reach nearly $240 billion by 2033, creating a fertile ground for companies like Apyx Medical. The company’s focus on its Helium Plasma Technology platform, coupled with the recently launched AYON Body Contouring System, positions it to capture a significant share of this expanding market.

Navigating a Competitive Landscape

While the growth potential is considerable, Apyx Medical operates in a fiercely competitive landscape. Established players like InMode, Cynosure, and Cutera are all vying for market share, constantly innovating and introducing new technologies. To differentiate itself, Apyx Medical is emphasizing the unique benefits of its Helium Plasma Technology, which offers precise and controlled tissue remodeling with minimal downtime. “The key is to deliver superior clinical outcomes and a positive patient experience,” explained a leading dermatologist familiar with the company's technology. “Patients are increasingly seeking minimally invasive procedures that deliver noticeable results without the risks and extended recovery periods associated with traditional surgery.”

The recent submission of a 510(k) premarket notification to the FDA for label expansion of the AYON Body Contouring System to include power liposuction further demonstrates Apyx Medical’s commitment to innovation. If approved, this expansion would position the AYON system as the first fully integrated body contouring system, offering a comprehensive solution for fat removal, tissue contraction, and skin tightening. According to a regulatory filing, the company anticipates a decision from the FDA in the first half of 2026.

Financial Health and Investor Confidence

The $10 million offering provides Apyx Medical with a much-needed financial boost, allowing it to strengthen its balance sheet and pursue strategic growth initiatives. While the company has demonstrated consistent revenue growth in recent quarters, it has also faced challenges related to profitability and cash flow. The recent offering will enable Apyx Medical to invest in sales and marketing efforts, expand its distribution network, and fund ongoing research and development.

“The company has a compelling technology and a clear vision for the future,” noted an analyst covering the medical device sector. “The key will be to execute its strategy effectively and deliver consistent financial results. This offering provides the financial flexibility needed to achieve those goals.” The company’s latest earnings report revealed a revenue increase of 12% year-over-year, bolstered by strong sales of both Renuvion and the AYON system.

The offering was managed by Lucid Capital Markets, which has a track record of successfully executing public offerings for emerging growth companies. While the offering does result in dilution for existing shareholders, the long-term benefits of increased financial flexibility and accelerated growth are expected to outweigh the short-term impact. Investors appear to be confident in the company’s prospects, as evidenced by the steady trading volume of APYX stock following the announcement of the offering. The company aims to leverage the funds to bolster its position in the burgeoning field of surgical aesthetics and build upon its successful trajectory in the market.